Upon completion of this activity, the participant should be able to:

• Define the impact of BAK and other preservatives on iatrogenic ocular surface disease in glaucoma patients on chronic therapy, and its influence on patient satisfaction and compliance over time
• Identify the prevalence of BAK/preservative-related adverse events among glaucoma patients on various therapies and how these symptoms may change over time
• Review the perceptions of preservatives on a global scale and discuss changes observed in patients after implementing preservative-free therapies

Jointly Provided by Evolve Medical Education and The Fundingsland Group.

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC (Evolve) and The Fundingsland Group. Evolve is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
Evolve Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Robert J. Noecker, MD, MBA

Ophthalmic Consultants of Connecticut
Yale University
Quinnipiac University
Fairfield, CT

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

The following faculty/staff members have the following financial relationships with ineligible companies.

Robert J. Noecker, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Bausch + Lomb, BVI, Elios Vision, EyePoint Pharmaceuticals, Glaukos, Iridex, ISP, MST, New World Medical, Nova Medical, Ocular Therapeutix, Sight Sciences, Sun Pharma, and Théa Pharma. Grant/Research Support: Alcon, Allergan, BVI, Glaukos, Iridex, ISP, MST, New World Medical, Nova Medical, and Sight Sciences. Shareholder: ISP, Mati Pharmaceutical, Ocular Therapeutix, and Sight Sciences. Speaker’s Bureau: Allergan, Glaukos, Iridex, MST, Nova Medical, and Ocular Therapeutix.

The Evolve and The Fundingsland Group staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, or Théa Pharma.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.